RCaz/eu-funding-proposals-sft huggingface dataset:
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write clear, measurable objectives and define the scope for the project 'PRocurEments of innoVativE, advaNced systems to support security in public Transport' (PREVENT) under Horizon 2020.

assistant: **Objectives**

PREVENT - PRocurEments of innoVativE, advaNced systems to support security in public Transport - focuses on pre-empting attacks in public transport by enabling earlier detection of terrorists and potentially dangerous objects, tracking of detected individuals or situations and coordinating the response of security forces. This focus is shared, from the start, by 22 organisations from 10 countries, public transport operators, security forces, public buyers, city authorities of which 12 are consortium partners and 10 are members of the PREVENT User Observatory Group (UOG). PREVENT implements a progressive and iterative process to deliver 6 jointly defined Common Security Scenarios that capture threats and vulnerabilities. It also delivers a vulnerabilities and threats taxonomy directly applicable to the public transport world. For these scenarios, PREVENT undertakes a gap analysis between available solutions, existing standards, on-going research and identified needs, from which it elaborates a multi-dimensional roadmap of innovations and solutions. The roadmap is an online interactive tool that feeds the sustainability of PREVENT’s community. The highest priority innovations in the roadmap are selected by practitioners and public buyers to define a Common Challenge. This Common Challenge serves as the basis for a PCP, for which the buyers’ group is created, the lead buyer is selected, tender documents are generated. PREVENT includes a governance mechanism that ensures that the different phases are open to additional practitioners and public buyers. PREVENT includes a Security Advisory Board to manage the confidentiality of the sensitive knowledge generated by its activities, and a GDPR advisor to guide the elaboration of a Common Challenge fully compliant with Europe’s p
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft an impact statement for 'Improving kidney transplantation outcome with Renaparin® for patients with End-Stage Renal Disease by attenuating graft ischemia reperfusion injury', explaining its relevance to EU policy priorities under Horizon 2020.

assistant: **Impact**

This project will validate the safety and efficacy of Corline Biomedical’s pharmaceutical compound Renaparin®, a novel cell replacement technology used to coat the lining of the blood vessels of kidneys prior to transplantation. Donor kidneys lack natural blood flow while awaiting transplantation. This  can lead to ischemia (a shortage of oxygen and glucose supply to the kidney tissue). When connected to the recipient’s blood flow, this in turn leads to ischemia reperfusion injury (IRI). Given the alarming shortage of organs available for transplantation in the EU and internationally, the prevention of IRI has become a top priority for the transplantation community. Transplantation surgeons and nephrologists emphasise the pressing need for safe and effective technologies which can improve the outcome of kidney transplantation and extend donor criteria. Renaparin® is used when the kidney has been extracted from the donor and is stored in preservation solution awaiting transplantation. There, it binds to, replaces, repairs and protects damaged kidney cells on the endothelium of the vascular wall. As a result, a kidney is less likely to activate the host’s innate immune system, which increases the chances of organ survival and substantially reduces the likelihood of organ rejection.The research performed in preparation of further development of Renaparin® strongly supports the drug’s potential to increase the success of kidney transplantation. The activities proposed in this project will bring Renaparin® through a Phase I/IIa clinical trial in humans. The produced clinical safety data and preliminary clinical efficacy data will constitute the basis for further clinical development and commercialisation of the product. Corline’s strategic focus lies on establishing Renapari
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose the 'Concept and Approach' section for a Horizon 2020 proposal on 'Unravelling cross-presentation pathways using a chemical biology approach'.

assistant: **Concept**

Immune therapies are therefore currently being pursued to reinvigorate the immune reaction against tumours. This is not trivial, as the right type of immune cells must be activated against a tumour-specific antigen. One method to achieve this is by targeting tumour antigens to certain cross-presentation-promoting receptors on antigen presenting cells. The most intriguing of these is the mannose receptor (MR) as the method by which it does this is unknown.  This glycoprotein-binding receptor appears to have two functions on APCs: general uptake-enhancement and, in certain isolated cases, cross-presentation-enhancment. What ligand parameters are important in causing cross-presentation enhancement is not known. Current tools, such as anti-MR antibodies and randomly glycosylated ligands fail to selectively enhance cross-presentation. The main aim of this proposal is to determine what structural parameters of the glycoprotein antigen result in enhanced cross-presentation upon MR-ligation. I will synthesise a library of biologically traceable single glycoform ligands - with controlled variation in glycan nature, stoichiometry and positioning - for the MR and study differences in uptake, routing and antigen presentation. A 2nd aim is to uncover what happens to the antigen after uptake by the MR. I.e. whether changes in antigen routing and proteolysis are responsible for enhanced cross presentation of different glycoforms. A 3rd aim is to develop a new method to study the kinetics of surface appearance of epitopes without T-cell reagents to quantify differences between glycoforms. With this approach I aim to gain new insight into methods for enhancing cross-presentation resulting in improved immune therapies against cancer. My background in carbohydrate and protein modification
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe how 'Art of Darkness as Cultural Heritage of Urban Landscape' will create measurable scientific, societal and economic impact aligned with Horizon Europe.

assistant: **Impact**

The Art of Darkness as Cultural Heritage of Urban Landscape (Art of Darkness) project aims to preserve and develop cultural heritage sites throughout Europe with a better understanding of the cultural, aesthetic, and sustainability values of darkness, which are important to the well-being of humans and nature. The project raises awareness of and explores well-considered darkness with high-quality architectural lighting design and light art as an asset in relation to cultural heritage, which can be cherished and harnessed to boost cultural-led innovation and attract strategic investments to cultural heritage and Cultural and Creative Industries (CCI). This is achieved through creating a Europe-wide collaborative network of 3 cities, 5 research institutions and 2 societies, which conduct 5 artistic pilot trials in cultural heritage sites in 5 countries. The pilot trials develop design strategies and solutions for more sustainable, aesthetic and socially feasible dark-time experiences through co-design with local stakeholders. The piloting process, which consists of context mapping, co-design, pilot production and evaluation processes, brings together researchers, CCIs professionals (e.g. artists, lighting designers, architects), citizens, local societies, and municipality actors. Thus, methodology of the project is transdisciplinary, participatory and integrative: The disciplines included in the project consortium are architecture, light-art, cultural heritage, urban design and planning, lighting design, photometrics, engineering, media- and neurotechnology, environmental psychology, cultural anthropology, scenography, and performing arts. Importantly, the evaluated results are integrated into the Art of Darkness Piloting Model to be replicated in other cities and regions
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe the novelty, innovation potential and advance beyond the state of the art for 'Functional Keratin Kerasol' (KERASOL).

assistant: **Innovation**

Keratin as a key structural material has been used in cosmetics as a raw material in skin and hair care products in a generalized way since several years, marking a trend in all cosmetic manufacturers offering keratin treatment lines. The human body takes advantage of this cosmetic contribution of keratin through contact with products that Incorporate it, getting the protein to adhere to the damaged areas in order to regenerate the skin and hair. Now, although the exploitation of these keratin sources is a well-known industrial process, most of the methods of obtaining keratin from agricultural waste are based on very aggressive thermal or chemical treatments. As a result of the aggressiveness of these treatments, the protein obtained is much denatured and has lost most of the properties that make keratin a protein of industrial interest.In this context with our project, we bring to the market a new solution, which will not only reduce the environmental impact of a waste produced in slaughterhouses, but optimize the keratin production process for cosmetics purposes too, in a sustainable, reliable and cost-effective wayBased on an exclusive patent whose rights we have acquired, we obtain a new keratin product as no one has yet achieved it. By its method of obtaining we have got a unique product in the world that preserves all the functional properties of keratin and therefore its bio availability for the human being. We obtain our product at a low cost thanks to the low energy needs in the production and to the raw material that we use at cost 0, the hair and the hooves of pigs, a residual waste of meat processing. Our processing plant will produce 1.500Kg/day of keratin KERASOL, a registered trademark of our property, which will make the difference in the cosmetic kerat
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain the overall concept, methodology and approach for the project 'Molecular mimicry as a key parameter shaping T cell immunity' (MIMIC).

assistant: **Concept**

Scientific Challenge: Immunotherapy has revolutionized cancer treatment, yet only a minor fraction of patients respond to frequently used immunotherapeutic treatments. T cell recognition of peptide-major histocompatibility (pMHC) class I complexes is essential to maintain immune surveillance and eliminate cancerous cells. Numerous products of genetic and epigenetic alterations can serve as targets for T cell recognition of cancer,  yet our capacity to predict what MHC-embedded targets T cells can recognize on the surface of cancer cells is still poor, with a less than 5% hit rate. While we have robust tools for prediction of antigen presentation, we still have very limited understanding of the factors driving immunogenicity – i.e. which of the presented targets will give rise to a T cell recognition. A fundamental mechanism influencing T cell recognition is molecular mimicry.  It has long been proposed that the ability of a given T-cell receptor (TCR) to recognize multiple different pMHC complexes is essential to provide immunological coverage of all potential pathogens that we may encounter. T cell epitopes, that at first glance appear very different, may have structural similarities once embedded in the MHC I binding groove, and hence appear similar to the given TCR (molecular mimicry).Objective: In MIMIC, I will determine the role of molecular mimicry in T cell recognition and demonstrate how pre-existing immunity may shape the T cell recognition of cancer antigens. I will use the SARS-CoV2 infection as a model system to understand molecular mimicry, and apply the learnings from this to cancer immunogenicity. Expected outcome: I predict that by understanding the influence of molecular mimicry, the rules governing the immunogenicity of T cell epitopes can be determine
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose the 'State of the Art and Innovation' section for a Horizon Europe proposal on 'Connecting Greek and Portuguese Innovation Ecosystems to Develop a Hub for Infectious Diseases Diagnostic Solutions at the Point-of Care – Tackling Cross-border Threats'.

assistant: **Innovation**

The aim of DxHub is to develop a strong ecosystem that mutually reinforces actors from two widening countries to consolidate individual efforts and allow for rapid and on the spot accurate diagnosis of infectious diseases within One-Health. The ecosystems in Crete, GR and the Oeiras region, PT, have already demonstrated a rich portfolio of activities to tackle the problem of efficient diagnosis outside a centralized lab. The DxHub will bring the two isolated regions together and, through a common R&I plan, accelerate innovations in diagnostics into impactful solutions by embracing the quadruple helix of main innovation players. Cutting-edge R&Is will be promoted based on joint research, innovation and investment plans. Pilot projects will be used to interlink academia with business providing solutions addressing the health, veterinary and agri/food sectors, all in line with both regions’ strategic priorities. In parallel, the efficient communication, dissemination and exploitation of the DxHub outcomes to the broad ecosystem will ensure high societal impact as a result of the co-development and acceptance of the new innovations by all actors of the quadruple helix. We expect that by building strong links between all payers of DxHub will foster knowledge transfer leading to the creation of new jobs and of attractive and sustainable place-based innovation ecosystems.


**Keywords:** One-Health, Diagnostics, Ecosystem, Valorisation, Excellence, Hub
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft an executive summary for the EU project 'High Performance Electric Outboard Motor System and Supply Chain Innovation' (2014-2020) targeting Horizon 2020.

assistant: **Abstract**

In Europe there are 4.8m boats with outboard engines and 99% percent of them run on petrol or diesel. These conventional boat motors are highly polluting (emitting CO2, methane, carbon monoxide and other substances), burn a massive amount of fossil fuel and are excessively noisy. So why aren’t we electrifying boats like we’re electrifying cars? Small and light boats can indeed run on electric engines; however, the current outboard solutions have performance limitations and are very expensive. Larger boats require powerful, higher-performance electric engines (over 80 horsepower) which are cost prohibitive due to the low availability of components and the resulting high production costs associated with them. We at pHatching have the solution. We offer a new electric outboard engine design with a customised belt-drive and horizontal drive shaft, allowing us to stack multiple small engines in a modular system. At the same time, we take advantage of the established supply chain and high-volume standard components from the auto industry to dramatically lower the cost of production and maintenance (53% less than current outboard solutions), thereby eliminating the major market barrier to adoption of viable high-performance electric marine engines. We also provide a useful second life for used electric vehicle batteries.As a result of combining a new design with an innovative use of auto parts, our new electric outboard engine is: (1) green, quiet and powerful (up to 200 hp); (2) easily retrofitted into existing boats; (3) modular and scalable and (4) highly efficient in terms of production and operation.pHatching was founded in 1989 in Sweden. Our innovation fulfils a large opportunity in the marine industry, enabling electrification of marine transport. A 5-year projection s
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write clear, measurable objectives and define the scope for the project 'Enhancing Research and innovAtion dimension of the University of Zilina in intelligent transport systems' (ERADIATE) under Seventh Framework.

assistant: **Objectives**

The ERAdiate project is aimed at unlocking and strengthening the research potential and promoting excellence of the University of Zilina (UNIZA) as well as of the Zilina region in the field of Intelligent Transport Systems (ITS). Systematic development of human resources, effective exploitation of unique research infrastructures and advanced transformations of the institution steered towards enhanced competitiveness in the European Research Area (ERA) are the key instruments to reach the ERAdiate goals. The project focuses on sustainable development of human resources and key competences under leadership of an experienced scientist and manager, an ERA Chair Holder, and his/her team. Major challenges such as creating competitive environment, increasing of critical mass of excellent researchers, significant improvement of the UNIZA performance in competitive research funding, implementation of the ERA culture, contribution to growth and jobs based on the SMART specialization strategies, are addressed. Synergic effect between cohesion funds and research funding is the corner-stone for building up a unique research and innovation hub located in the Zilina region and oriented on global societal and environmental challenges connected to the solving of transportation issues with implementation of the ITS. Realization of the ERAdiate project will enhance the UNIZA and the Zilina region performance in research, innovation as well as education for the benefits of enlarged Union.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe how 'DISC care™ , the Hernia Blocking System to prevent Lumbar Disc Re-Herniation' will create measurable scientific, societal and economic impact aligned with Horizon 2020.

assistant: **Impact**

Lumbar disc herniation occurs when the intervertebral disc breaks and its nucleus bursts out pressing the nerves. It causes extreme back and leg pain, numbness and disability. To relieve the pain, a surgical intervention (discectomy) is the standard of care, consisting of removing the herniated material. Disc herniation is the most frequent cause of spine surgery for working-age patients and in 2019 more than 1M lumbar discectomies were performed WW. Although discectomy may work in some cases, a high portion of patients have a high risk of re-herniation through the same disc defect, requiring a costly and complex re-operation. To avoid re-herniation, some surgeons remove a larger amount of nucleus, making it unlikely to re-herniate, but compromising the disc functionality and causing chronic back pain. NEOS Surgery has developed the DISC care™ Hernia Blocking System, an implantable strong barrier that prevents re-herniation while allowing surgeons to remove the minimum disc tissue. DISC care™ will solve an unmet clinical need while reducing healthcare costs. The internationally patented DISC care™, has completed several years of development and pre-clinical testing with excellent results. The product is now ready to overcome the final barriers for its market launch in 2023: clinical trial, complete product range and CE-marking under the new EU MDR. The DISC care™ will enter a “Blue Ocean” market segment, being the first Hernia Blocking device from a European company and the second worldwide. The DISC care™ will radically impact NEOS turnover, with an exponential growth 2027. Moreover, it will accelerate NEOS growth, creating a very profitable financial structure for future expansion. NEOS multidisciplinary team will be key for the DISC care™ success: we have the experie